Key Insights

Highlights

Success Rate

97% trial completion (above average)

Published Results

62 trials with published results (29%)

Research Maturity

172 completed trials (81% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

2.4%

5 terminated out of 212 trials

Success Rate

97.2%

+10.7% vs benchmark

Late-Stage Pipeline

36%

77 trials in Phase 3/4

Results Transparency

36%

62 of 172 completed with results

Key Signals

62 with results97% success

Data Visualizations

Phase Distribution

177Total
Not Applicable (28)
Early P 1 (2)
P 1 (44)
P 2 (26)
P 3 (42)
P 4 (35)

Trial Status

Completed172
Unknown11
Recruiting9
Active Not Recruiting8
Terminated5
Not Yet Recruiting3

Trial Success Rate

97.2%

Benchmark: 86.5%

Based on 172 completed trials

Clinical Trials (212)

Showing 20 of 20 trials
NCT06436703Phase 1CompletedPrimary

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

NCT04288921CompletedPrimary

Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites

NCT06684379Phase 1Recruiting

Study on Safety and Efficacy of Two Doses of PRS CK STORM in the Modulation of the Cytokine Storm in Patients With Acute Respiratory Infection Caused by SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV)

NCT06807840RecruitingPrimary

Flu Infection at UPHS

NCT06087640Phase 3Active Not RecruitingPrimary

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

NCT07121192Phase 2CompletedPrimary

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

NCT03330132Phase 4CompletedPrimary

Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong

NCT04576377Phase 4CompletedPrimary

Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures

NCT05422326Phase 2CompletedPrimary

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

NCT06824519Phase 1RecruitingPrimary

Clinical Trials of Quadrivalent Influenza Vaccine

NCT05648448Phase 2Recruiting

A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza

NCT07204964Phase 2Active Not RecruitingPrimary

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

NCT05921448Early Phase 1Active Not RecruitingPrimary

Vaccine Pandemic Preparedness Through Airway Immunology Characterization

NCT05227001Phase 1CompletedPrimary

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

NCT07393685Not Yet Recruiting

Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD

NCT05446740Phase 1CompletedPrimary

A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

NCT06431607Phase 2CompletedPrimary

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

NCT07161739Not ApplicableActive Not Recruiting

Vaccination Nudges From Pharmacists

NCT05108818Phase 4RecruitingPrimary

Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults

NCT06382311Phase 1CompletedPrimary

A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults

Scroll to load more

Research Network

Activity Timeline